Trial of retinol and isotretinoin in skin cancer prevention: A randomized, double-blind, controlled trial

Norman Levine, Thomas E. Moon, Brenda Cartmel, Jerry L. Bangert, Steven Rodney, Qiong Dong, Yei Mei Peng, David S Alberts

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

The objective of this study was to examine the effect of retinol and isotretinoin on the incidence of nonmelanoma skin cancer in high-risk subjects. A total of 525 participants with a history of at least four basal cell carcinomas (BCCs) and/or cutaneous squamous cell carcinomas (SCCs) were entered into a randomized, double-blind, placebo-controlled trial, performed in free-standing study clinics. Participants were randomly assigned to receive oral retinol (25,000 units), isotretinoin (5-10 mg), or placebo supplementation daily for 3 years. The time to first new occurrence of BCC or cutaneous SCC was used as the outcome measure. During the study period, 319 BCCs and 125 cutaneous SCCs were diagnosed clinically and pathologically. There were no differences between those who received retinol, isotretinoin, or the placebo, with regard to the time to first occurrence or to the total number of tumors noted. No beneficial effects were noted with regard to the prevention of nonmelanoma skin cancer with either retinol or isotretinoin.

Original languageEnglish (US)
Pages (from-to)957-961
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume6
Issue number11
StatePublished - 1997

Fingerprint

Isotretinoin
Skin Neoplasms
Vitamin A
Basal Cell Carcinoma
Squamous Cell Carcinoma
Placebos
Skin
Ambulatory Care Facilities
Outcome Assessment (Health Care)
Incidence
Neoplasms

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Trial of retinol and isotretinoin in skin cancer prevention : A randomized, double-blind, controlled trial. / Levine, Norman; Moon, Thomas E.; Cartmel, Brenda; Bangert, Jerry L.; Rodney, Steven; Dong, Qiong; Peng, Yei Mei; Alberts, David S.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 6, No. 11, 1997, p. 957-961.

Research output: Contribution to journalArticle

Levine, N, Moon, TE, Cartmel, B, Bangert, JL, Rodney, S, Dong, Q, Peng, YM & Alberts, DS 1997, 'Trial of retinol and isotretinoin in skin cancer prevention: A randomized, double-blind, controlled trial', Cancer Epidemiology Biomarkers and Prevention, vol. 6, no. 11, pp. 957-961.
Levine, Norman ; Moon, Thomas E. ; Cartmel, Brenda ; Bangert, Jerry L. ; Rodney, Steven ; Dong, Qiong ; Peng, Yei Mei ; Alberts, David S. / Trial of retinol and isotretinoin in skin cancer prevention : A randomized, double-blind, controlled trial. In: Cancer Epidemiology Biomarkers and Prevention. 1997 ; Vol. 6, No. 11. pp. 957-961.
@article{2953dbd3a561483f87bb60dd9c1dd761,
title = "Trial of retinol and isotretinoin in skin cancer prevention: A randomized, double-blind, controlled trial",
abstract = "The objective of this study was to examine the effect of retinol and isotretinoin on the incidence of nonmelanoma skin cancer in high-risk subjects. A total of 525 participants with a history of at least four basal cell carcinomas (BCCs) and/or cutaneous squamous cell carcinomas (SCCs) were entered into a randomized, double-blind, placebo-controlled trial, performed in free-standing study clinics. Participants were randomly assigned to receive oral retinol (25,000 units), isotretinoin (5-10 mg), or placebo supplementation daily for 3 years. The time to first new occurrence of BCC or cutaneous SCC was used as the outcome measure. During the study period, 319 BCCs and 125 cutaneous SCCs were diagnosed clinically and pathologically. There were no differences between those who received retinol, isotretinoin, or the placebo, with regard to the time to first occurrence or to the total number of tumors noted. No beneficial effects were noted with regard to the prevention of nonmelanoma skin cancer with either retinol or isotretinoin.",
author = "Norman Levine and Moon, {Thomas E.} and Brenda Cartmel and Bangert, {Jerry L.} and Steven Rodney and Qiong Dong and Peng, {Yei Mei} and Alberts, {David S}",
year = "1997",
language = "English (US)",
volume = "6",
pages = "957--961",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Trial of retinol and isotretinoin in skin cancer prevention

T2 - A randomized, double-blind, controlled trial

AU - Levine, Norman

AU - Moon, Thomas E.

AU - Cartmel, Brenda

AU - Bangert, Jerry L.

AU - Rodney, Steven

AU - Dong, Qiong

AU - Peng, Yei Mei

AU - Alberts, David S

PY - 1997

Y1 - 1997

N2 - The objective of this study was to examine the effect of retinol and isotretinoin on the incidence of nonmelanoma skin cancer in high-risk subjects. A total of 525 participants with a history of at least four basal cell carcinomas (BCCs) and/or cutaneous squamous cell carcinomas (SCCs) were entered into a randomized, double-blind, placebo-controlled trial, performed in free-standing study clinics. Participants were randomly assigned to receive oral retinol (25,000 units), isotretinoin (5-10 mg), or placebo supplementation daily for 3 years. The time to first new occurrence of BCC or cutaneous SCC was used as the outcome measure. During the study period, 319 BCCs and 125 cutaneous SCCs were diagnosed clinically and pathologically. There were no differences between those who received retinol, isotretinoin, or the placebo, with regard to the time to first occurrence or to the total number of tumors noted. No beneficial effects were noted with regard to the prevention of nonmelanoma skin cancer with either retinol or isotretinoin.

AB - The objective of this study was to examine the effect of retinol and isotretinoin on the incidence of nonmelanoma skin cancer in high-risk subjects. A total of 525 participants with a history of at least four basal cell carcinomas (BCCs) and/or cutaneous squamous cell carcinomas (SCCs) were entered into a randomized, double-blind, placebo-controlled trial, performed in free-standing study clinics. Participants were randomly assigned to receive oral retinol (25,000 units), isotretinoin (5-10 mg), or placebo supplementation daily for 3 years. The time to first new occurrence of BCC or cutaneous SCC was used as the outcome measure. During the study period, 319 BCCs and 125 cutaneous SCCs were diagnosed clinically and pathologically. There were no differences between those who received retinol, isotretinoin, or the placebo, with regard to the time to first occurrence or to the total number of tumors noted. No beneficial effects were noted with regard to the prevention of nonmelanoma skin cancer with either retinol or isotretinoin.

UR - http://www.scopus.com/inward/record.url?scp=0030840112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030840112&partnerID=8YFLogxK

M3 - Article

C2 - 9367070

AN - SCOPUS:0030840112

VL - 6

SP - 957

EP - 961

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 11

ER -